Iberia Pharmaceuticals India Limited

This section provides an overview of the industry context, primarily referencing external industry research reports. It discusses the projected global economic growth, the impact of geopolitical tensions, and the outlook for the Indian economy. It details various economic indicators such as GDP growth projections, sectoral growth in Gross Value Added (GVA), and consumer price inflation trends. Furthermore, it mentions the influence of weather patterns like El Niño and the impact of geopolitical conflicts on supply chains for various industries.

The provided text covers various macroeconomic and demographic trends in India, including monetary policy stances, industrial growth, state-wise production metrics, household savings patterns, and demographic shifts. It discusses the impact of various factors like monsoon expectations, industrial production growth, the performance of different states in terms of per capita SDP, the shift in household savings towards physical assets, and the growth in disposable income and consumer spending. Furthermore, it details trends in population growth, urbanization, and the movement of the USD exchange rate.

The section discusses macroeconomic factors, including fluctuations in the INR–USD exchange rate, and the impact of geopolitical tensions on import costs for various industries. It also covers trade negotiations between India and the US, including proposed tariff rates for certain sectors. Furthermore, the text details the growth of the global pharmaceutical industry, the structure of its value chain, and the specific dynamics of the Indian pharmaceutical industry. This includes market size, growth drivers, market segmentation into generic drugs and OTC medicines, and the competitive advantages of India in manufacturing.

The pharmaceutical industry in India shows significant activity across various segments, including the production of bulk drugs (APIs) and vaccines, where India maintains a leading global position. India is a major producer of APIs, with export dominance, while also working to reduce reliance on imports. The sector also encompasses Contract Research and Manufacturing Services (CRAMS), which offer outsourced services like drug manufacturing and clinical research. Furthermore, the market is seeing growth in traditional medicine systems, biologics, nutraceuticals, and medical devices, alongside a growing trend of outsourcing to Contract Development and Manufacturing Organizations (CDMOs).

The text discusses the growing presence of Indian players in regulated markets, particularly in the US, creating opportunities for Indian Contract Development and Manufacturing Organizations (CDMOs) to serve large pharma companies for large-scale production and exports. The industry is seeing a shift towards complex therapies like biologics and biosimilars, demanding CDMOs with advanced technical capabilities in areas such as fermentation and aseptic filling. Furthermore, there is a growing need for expertise in innovative drug delivery systems like nanoparticles and injectables. The pharmaceutical industry is also shifting towards asset-light models, where CDMOs provide fully equipped infrastructure and technical expertise to allow companies to meet production demands without significant capital expenditure. Regulatory aspects involve various bodies like CDSCO and DCGI, and changes to rules aim to simplify processes, while compliance with GMP standards is mandatory for maintaining licenses. The text also covers market dynamics for the Cardio Diabetic segment, noting the high risk associated with cardiovascular diseases and diabetes in India, and the growth drivers in these markets.

The provided text details various types of cardiac devices used for treating heart rhythm issues, including ICDs, pacemakers, and VADs, alongside diagnostic tools like MRI and CT for cardiac imaging. It also covers treatments for blocked arteries such as coronary stents and the use of Cardiac Resynchronization Therapy (CRT) devices. The text highlights market growth drivers for cardiovascular devices in India, such as the popularity of minimally invasive treatments and the aging population. Furthermore, the text discusses the expanding dermatology and aesthetics markets, which are growing due to increased awareness of skin health and disposable income, with various treatments like botulinum toxins, dermal fillers, chemical peels, and mesotherapy gaining traction.

The text details various aesthetic and dermatology treatments gaining traction in India, including thread lifts, exosomes, and PDRN for rejuvenation. It also covers the growth of energy-based aesthetic devices, clinical dermatology segments like acne, psoriasis, and pigmentation disorders, and the market for derma cosmetics. The market for derma cosmetics is expanding due to consumer awareness and a preference for comprehensive skincare. Furthermore, the market for oral supplements is growing, driven by health awareness and the need for nutritional support.

The text discusses the evolving landscape of the supplement market, noting a consumer shift towards natural, 'clean-label' alternatives over synthetic additives. It details specific segments for women's and men's health supplements, highlighting product types for hormonal balance, fitness, and mental well-being. Furthermore, the text covers distribution channels, including online and offline channels for cosmetics, and the B2B channel for institutional buyers. The market analysis also covers the aesthetic market, which is expanding due to non-surgical procedures, rising disposable incomes, and changing consumer perceptions, alongside advancements in dermatological technologies.

The Indian aesthetic dermatology market is experiencing growth driven by global trends favoring non-invasive procedures like Botox, fillers, lasers, and HIFU, alongside the popularity of chemical peels and cosmeceuticals. The sector is characterized by a dual focus on treating medical conditions and addressing cosmetic needs, with advancements in clinical dermatology involving biologics and laser therapies, and derma cosmetics surging for anti-aging benefits. Key market drivers include increased consumer awareness, lifestyle changes, and the rise of medical tourism. However, the market faces challenges such as high treatment costs, limited rural awareness, and regulatory hurdles. Furthermore, the pharmaceutical supply chain is vulnerable due to reliance on imports for raw materials, and the cardio-diabetic segment faces pressure from generic competition and increasing regulatory scrutiny.

This section describes several pharmaceutical and healthcare companies, detailing their business operations, product portfolios, and market positioning. Iberia Pharmaceuticals India Limited focuses on marketing and distributing pharmaceutical, derma cosmetic, and wellness products across dermatology, hair care, and cardio-diabetic segments. Glenmark Pharmaceuticals Limited is a global R&D-driven pharmaceutical company with operations across numerous countries and focuses on respiratory, dermatology, and oncology therapies. Torrent Pharmaceuticals Limited manufactures branded and generic formulations across cardiovascular, GI, CNS, and Vitamin/Mineral segments, with manufacturing facilities approved by various international regulatory bodies. Zydus Lifesciences Limited has a broad portfolio including generics, branded generics, specialty formulations, and consumer wellness products, with a significant presence in the US generic market. Eris Lifesciences Limited focuses on branded generics in chronic and acute segments across various therapeutic areas. IPCA Laboratories Limited is a fully integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs, with a diverse global presence.

Iberia Pharmaceuticals India Limited is an Indian pharmaceutical and derma cosmetics company offering a diverse portfolio across aesthetic dermatology, hair care, cardio-diabetic, and general therapeutics. The company markets and distributes various products under its own brands and those of foreign brands, catering to a wide range of skin, hair, cardiovascular, diabetic, and anti-aging concerns. The company's product portfolio includes pharmaceutical drugs, derma cosmetic products, and over-the-counter solutions for healthcare and aesthetic use.

The company's product portfolio spans several key areas, including dermatology and aesthetic care, which addresses various skin and hair conditions. The portfolio includes numerous products categorized for different skin concerns, such as moisturizing creams, cleansing gels, and anti-dark spot treatments. Furthermore, the company operates in the therapeutic pharmaceuticals segment through its Metacare division, focusing on cardiovascular and metabolic disorders. The company maintains an extensive pan-India distribution network, supported by a large team of medical representatives and stockists, and has established track records in the market since 2013. The company is also pursuing backward integration by establishing its own manufacturing facilities.

The company intends to expand its market reach into foreign markets, specifically targeting South Asia and the Middle East by appointing exclusive distributors for its brands in Nepal, Sri Lanka, Saudi Arabia, and the United Arab Emirates. The company employs an integrated marketing strategy involving healthcare professional interactions, educational initiatives, merchandise, and digital outreach to build brand awareness. Furthermore, the company has diversified its product portfolio beyond dermatology and derma cosmetics into the cardio-diabetic segment with the launch of the proprietary brand Metacare, which offers products for managing chronic conditions like hypertension and diabetes. The overall product portfolio covers prescription and over-the-counter products addressing various skin, hair, cardiovascular, diabetic, and wellness needs.

The company offers various product lines under different brands, including Epidure for skin barrier repair, L-trum and Itruf for antifungal treatments, Bilhyde for urticaria, Ozecit for impetigo, and Tofa-AD for autoimmune skin disorders. KeyCi is an online exclusive cosmetic brand focused on the premium skincare segment, while Metacare is a proprietary brand for therapeutic pharmaceuticals targeting cardiovascular and metabolic health. Sesderma is a global derma cosmetics company that focuses on research and nanotechnology in skincare and has an exclusive distribution model in certain territories.

The company imports products into India and handles all sales, marketing, and distribution activities within the country. They market and distribute the entire portfolio of Sesderma products through a network of medical representatives and stockists/distributors for offline channels, while cosmetic products are made available via an appointed online distributor. The portfolio is dynamic, and as of the DRHP date, they distribute approximately 27 products comprising 69 SKUs under the Sesderma brand. Furthermore, the company has exclusive distribution rights for Mediderma products in various countries pursuant to an agreement with a partnership firm within its Promoter Group.

The company markets several product lines under different brands, including a professional peel, a medical device for collagen stimulation, and various skincare products targeting different skin concerns. The company has an exclusive distribution agreement with a French brand, Noreva, for skincare products in India, which involves importing and undertaking necessary regulatory registrations. Products are distributed through offline channels like stockists/distributors and medical representatives, as well as online channels via an appointed distributor. The company distributes approximately 7 products comprising 25 SKUs as of the Draft Red Herring Prospectus date.

The company maintains quality assurance through a combination of selected third-party manufacturing partners, regulatory compliance, product-specific evaluation, and independent testing. For pharmaceutical products, third-party manufacturers hold necessary licenses, and for cosmetic products, they adhere to rules, and the company conducts specific evaluations like PIPT and SPF studies. The company procures foreign brands like Sesderma, Mediderma, and Noreva through various distribution arrangements, either via direct imports or authorized distributors. The company has established a pan-India distribution network covering 26 states and 5 union territories. Revenue is primarily derived from the domestic market, although a small portion comes from foreign markets, and the company is expanding its foreign presence by appointing distributors in several overseas markets.

The company's supply chain involves two directly managed warehouses in Delhi, supplemented by two third-party logistics service providers for product distribution across India. The distribution strategy is divided into online and offline segments, with the offline approach focusing on a pan-India presence via a robust network and a dedicated team of 302 Medical Representatives. The company has established a wide distribution network through various distributors and stockists across numerous states and has also appointed distributors in Sri Lanka, Nepal, UAE, and Saudi Arabia. For online distribution, an exclusive agreement is in place with Iberia Skin Brands India Limited, which handles sales through its digital platforms. Furthermore, customer leads from certain brand websites are forwarded to the company for engagement.

The company utilizes various information technology infrastructure to support its business functions, including customer relationship management, finance, accounting, human resource management, and general business operations. Key systems employed include Salesforce for CRM, Tally for accounting, and HR One for human resource processes. Furthermore, the company has implemented SAP Business One as an ERP solution, alongside a Warehouse Management System (WMS) and Unique Serial Numbers (USNs) for inventory tracking. The company plans to incorporate automation and IT systems, including SCADA-enabled machines, for future manufacturing facilities. The company is subject to various industry-specific regulations, such as the Drugs and Cosmetics Act, 1940, and the Narcotic Drugs and Psychotropic Substances Act, 1985.

This section details various Indian laws and regulations that may apply to the company's operations, covering areas such as narcotic drugs, food safety, legal metrology, intellectual property, labour, and environmental compliance. It outlines specific requirements related to licensing, standards, documentation, and consumer protection across these diverse legal frameworks.

This section details various legal frameworks and regulations pertinent to the company's operations, including those related to wages, social security, taxation, foreign investment, competition, and corporate law. It outlines several laws such as the Code on Wages, the Code on Social Security, various GST laws, the Income-tax Act, and regulations governing foreign investment and securities. Furthermore, it covers aspects of competition law, the Companies Act, the Indian Contract Act, the Indian Stamp Act, and various laws governing the regulation of commercial establishments by local bodies. The text also provides a brief history of the company, including its incorporation, name changes, conversion to a public limited company, and amendments to its Memorandum of Association, along with milestones such as turnover and product launches.

The company has received recognition for excellence in the skincare and beauty sector and has been recognized as the 'Best Emerging Pharmaceuticals Company in India' by Business Outline. The company currently has no financial or strategic partners, and no defaults or rescheduling have occurred with financial institutions. Regarding corporate structure, the company has one subsidiary, Iberia Skin Brands Limited (U.K.), which is engaged in the distribution of derma cosmetic, skincare, and aesthetic care products. The company has not made any material acquisitions or divestments, nor has it undertaken any mergers, amalgamations, or asset revaluations since its incorporation. Furthermore, the company does not have any holding company, joint ventures, or associate companies as of the date of the DRHP.

This section provides detailed profiles for the company's directors, including personal and professional details, such as names, ages, designations, addresses, and terms of directorship. It also lists the companies in which the directors hold positions, including Indian private and public companies, and LLPs. The section further details the professional experience and responsibilities of the key personnel, such as the Managing Director, Whole-time Director, and Independent Directors, and includes various confirmations regarding conflicts of interest and arrangements with third parties.

This section details the remuneration and other terms of employment for various directors and promoters. It outlines specific provisions regarding fixed salaries, performance-linked incentives, perquisites, expense reimbursements, contributions to various funds, and clawback provisions. It also specifies the sitting fees for Non-Executive Directors and Independent Directors, noting that the company has not entered into contracts for appointing or fixing director remuneration in the two years preceding the DRHP date.

This section details various aspects related to the remuneration, shareholding, and director interests of the company. It specifies that no directors have received remuneration from subsidiaries in Fiscal 2026, and the company currently has no associates or joint ventures. Furthermore, it outlines rules regarding director interests in contracts, related party transactions, and loans. The text also covers provisions related to borrowing powers and the structure and composition of the Board, including the establishment of various Board-level committees.

This section details various functions and responsibilities delegated to different committees within the company, including the Nomination and Remuneration Committee (NRC), the Stakeholders’ Relationship Committee, the Corporate Social Responsibility Committee (CSR Committee), and the Initial Public Offering Committee (IPO Committee). It outlines the scope for these committees concerning director appointments, remuneration policies, shareholder grievances, CSR activities, and the process for conducting Initial Public Offerings.

This section details various powers and authorizations related to the issuance process, including consultation with regulatory bodies, the handling of shareholder participation, and the execution of necessary legal and procedural documentation. It outlines the company's authority to manage the entire issuance lifecycle, from drafting prospectuses to finalizing agreements with various intermediaries. Furthermore, it specifies powers related to listing the equity shares and establishing corporate governance policies.

The section details the qualifications and tenure of key personnel, including a Manager - Human Resources, and outlines various governance aspects such as the status of Key Managerial Personnel, relationships among promoters, and interest in related party transactions. It also specifies the shareholding structure of the promoters and clarifies the relationship dynamics between them.

The company has established a Non-Compete Agreement with Satnam & Company, which restricts Satnam & Company from engaging in other business activities and limits its ability to solicit customers or use the company's trade secrets to compete. Furthermore, there is no disclosed conflict of interest between the company's third-party service providers or suppliers and its Promoters, nor between the lessor of crucial immovable properties and the Promoters. The Promoters have not had any interest in property acquired by the company in the preceding three years or in transactions involving land acquisition, construction, or machinery supply.

This section appears to be an excerpt from an Independent Auditor's Examination Report concerning the restated consolidated financial information of Iberia Pharmaceuticals India Limited. It details the scope of the examination, which involved reviewing various financial statements and notes prepared by the Company. The financial information was prepared in accordance with accounting principles generally accepted in India, including Indian Accounting Standards (Ind AS), and was approved by the Board of Directors for inclusion in the Draft Red Herring Prospectus (DRHP).

The definitions section identifies the issuer as Iberia Pharmaceuticals India Limited, which is a public limited company incorporated under the Companies Act, 1956. The company's registered office is located in Delhi. The definitions also specify key personnel such as the Chief Financial Officer (CFO) and the Company Secretary and Compliance Officer. Furthermore, the section details various terms related to the issue process, including different types of bidders, the role of the Book Running Lead Manager (BRLM), and various aspects of the allotment procedure.

This section outlines various terms and definitions related to the public issue process, including investor types, documentation, and intermediaries. It details procedures for fund transfer, the role of various participants like Depository Participants, the nature of the prospectus, and the different categories of bidders such as QIBs, Retail Individual Bidders (RIBs), and Non-Institutional Bidders (NIBs). It also specifies the process for finalizing the issue price and the various accounts and agreements involved in the issuance.

This section primarily details the mechanism for submitting applications in public issues, specifically mentioning the use of the UPI mechanism for applications up to ₹ 5,0. It outlines the required parties for the application, including syndicate members, stock brokers, depository participants, and registrars. The text also lists various circulars and regulations that govern this process, including those from SEBI and Stock Exchanges.

This section primarily lists various SEBI regulations and circulars that are applicable to the context of the prospectus. It also details conventions regarding the jurisdiction (India and its territories), time, and currency. Furthermore, it specifies that financial data is derived from restated financial information, and clarifies the differences between Indian Accounting Standards (Ind AS) and Indian GAAP. The text also mentions the source of industry-related information, which is a report prepared by CARE Analytics and Advisory Private Limited.

This section discusses forward-looking statements within the Draft Red Herring Prospectus, cautioning investors that these statements are based on current plans, estimates, and expectations and that actual results may differ materially. The text lists various risks and uncertainties, including regulatory changes, economic conditions, market volatility, and operational issues, which could impact the company's business activities. Investors are cautioned not to place undue reliance on these statements as a guarantee of future performance.

This section details the capital structure of the company, including the authorized and issued share capital. It also provides a history of equity share allotments, including rights issues and private placements, which occurred over several years. The section also mentions a future bonus issue scheduled for January 30, 2026, and clarifies that no equity shares have been issued for consideration other than cash or through bonus issues since incorporation.

The section details various aspects related to the issue and holding of equity shares, including restrictions on issuing shares at a lower price than the issue price and limitations on the issuance of shares under schemes of arrangement. It also outlines provisions regarding employee stock option schemes, and clarifies the requirements for promoter shareholding, including minimum contribution and lock-in periods. Furthermore, it specifies rules concerning the pledgeability of promoter holdings and the transferability of locked-in shares among promoters and the promoter group.

This section details the shareholding pattern of the company as of the Draft Red Herring Prospectus date, including a breakdown by category. It also provides information on secondary transactions involving the promoter and promoter group, noting no such acquisitions were disclosed except as mentioned elsewhere. Furthermore, the text lists details of major shareholders holding 1% or more of the paid-up share capital, showing their holdings as of the prospectus date, 10 days prior, one year prior, and two years prior. It also outlines details regarding the acquisition prices of equity shares by promoters and the promoter group within the last three years.

The company has complied with relevant Companies Acts regarding share issuance since its inception, and no buy-back arrangements have been entered into by the company, its directors, or the Book Running Lead Managers. The company has not made any public issue or rights issue other than those disclosed previously. Furthermore, the company does not currently intend to alter its capital structure in certain ways for a specified period, and no financing arrangements have been made by the promoter group for the purchase of securities. The total number of equity share holders as of the draft prospectus date is specified, and all equity shares are held in dematerialized form.

The issue involves a fresh issue of equity shares up to 64,75,560 shares with a face value of ₹10, aggregating up to a certain amount. The net proceeds from this issue are proposed to be utilized for several purposes, including capital expenditure for machinery, repayment of outstanding borrowings, branding and marketing, funding working capital, and general corporate purposes. The utilization plan details the estimated deployment of these funds across different financial years, with provisions for utilizing internal accruals or other funds if the estimated utilization is not fully met.

The section details various proposed purchases and capacity utilization calculations for different production lines, including capacity for bottle output, batch production, and tube filling. It also outlines the plan to acquire specialized equipment such as HVAC & Clean Room Systems, Standard Production Plants, and various laboratory instruments. Furthermore, the company intends to utilize a significant portion of the net proceeds for debt repayment and other corporate purposes.

The company has detailed various loan agreements and the corresponding amounts outstanding, which include both secured and unsecured loans. The section also outlines the proposed utilization of net proceeds from the issue, primarily for marketing and brand promotion activities. Specific provisions detail the planned expenditure on offline marketing, such as events, merchandise, and gifts, as well as online marketing, including paid media and SEO initiatives. Furthermore, the company intends to use a portion of the net proceeds to fund incremental working capital requirements and another significant amount for capital expenditure for setting up a new manufacturing facility.

The company requires funding for various aspects of its operations, including capital expenditure for plant and machinery and incremental working capital to support a transition to an in-house manufacturing model. The working capital requirements are projected over several fiscal years, with projections showing significant changes due to the shift in business model. The company proposes to utilize a portion of the net proceeds from the issue to fund incremental working capital needs, primarily through internal accruals and borrowings. The remaining net proceeds are proposed for general corporate purposes.

The section details various aspects related to the issue, including the treatment of surplus amounts, confirmations from Chartered Accountants regarding the object details, and the breakdown of estimated issue-related expenses. It further outlines the various components of these expenses, such as fees payable to various parties, processing charges, and miscellaneous costs. The text also covers the handling of gross proceeds, the undertaking to deposit net proceeds with scheduled commercial banks, monitoring of fund utilization, and restrictions on using proceeds for trading or investments in other listed companies. Finally, it addresses the possibility of bridge financing and the process for varying the objects of the issue, along with confirmations that no part of the net proceeds will be paid to promoters or related parties.

The section details the basis for determining the issue price, which involves consultation with Book Running Lead Managers based on market demand and various quantitative, operational, and qualitative factors. Qualitative factors include the company's position as a Pan-India player, its diversified product portfolio, established distribution network, robust sourcing capabilities, strong liquidity, and experienced management. Quantitative factors are derived from Restated Consolidated Financial Statements, including Basic and Diluted Earnings Per Equity Share (EPS) for different fiscal years, as well as various financial ratios like P/E ratio, Return on Net Worth (RoNW), Net Asset Value (NAV), and Key Performance Indicators (KPIs).

This section presents various financial ratios and comparisons against industry peers, detailing performance metrics for different financial years. It includes comparisons of key ratios such as Current Ratio, Debt-equity ratio, Debt service coverage ratio, and various profitability and efficiency ratios. Furthermore, the text details the history of share issuances, including primary and secondary transactions, and provides information on the Weighted Average Cost of Acquisition (WACA) for specified securities.

This section confirms that the enclosed Statement, prepared by the Company and initialled by the auditors, provides information regarding possible special tax benefits available to the Company and its shareholders under various Indian tax laws. It clarifies that the availability of these benefits depends on the Company and shareholders fulfilling prescribed conditions. The statement is intended for general information to investors and is not a substitute for professional tax advice. Furthermore, it outlines limitations regarding the scope of benefits discussed and the reliance on information obtained from the Company.

This section, titled 'Statement of Tax Benefits,' clarifies the availability of special tax benefits to the company and its shareholders under Indian tax laws. It explicitly states that there are no special direct tax benefits available to the company under the Income-tax Act, 1961, or any other applicable law. Furthermore, there are no special indirect tax benefits available under applicable indirect tax laws, including the Goods and Services Tax laws. The statement also advises shareholders to consult their own tax advisors regarding the tax consequences of acquiring, holding, and disposing of equity shares, and it clarifies that the statement is for general information only.

This section details the reliance on audited financial statements and the consolidation process for the financial information of Iberia Skin Brands Ltd., a subsidiary. The financial statements were compiled from audited statements for the years ended March 31, 2026, 2025, and 2024, and the report confirms that adjustments were made retrospectively to reflect changes in accounting policies. Specific financial figures for the subsidiary as of March 31, 2026, were provided.

This section details the restated consolidated statement of cash flows for the years ended March 31, 2026, 2025, and 2024, covering operating, investing, and financing activities. The cash flow from operating activities showed a significant decrease across the three years, with net cash generated from operating activities declining from ₹159.97 Crore in FY26 to ₹74.84 Crore in FY24. Investing activities resulted in cash usage, primarily from the purchase of property, plant, and equipment. Financing activities showed substantial cash inflows from long-term borrowings and proceeds from the issue of equity share capital.

This section details various accounting treatments and recognition policies related to employee benefits, revenue recognition, discontinued operations, provisions, and contingent liabilities. It outlines specific standards used for revenue recognition based on the Ind AS 115 five-step model, defining when revenue is recognized for both goods and services. Furthermore, it describes the accounting for various financial items such as interest income, the treatment of discontinued operations, and the recognition criteria for provisions and contingent liabilities.

This section details the reconciliation of carrying amounts for various assets and liabilities over several fiscal years, including Capital Work in Progress, Other Intangible Assets, Right-of-Use Assets, and various financial provisions. The data shows fluctuations in these balances from 2024 to 2026, with specific figures provided for additions, depreciation, and net blocks. Furthermore, it presents detailed breakdowns of Deferred Tax Assets and Liabilities, including components like Property, Plant and Equipment, Intangible Assets, and Lease Liabilities.

This section provides historical data for various balance sheet items, including Property, Plant and Equipment, Intangible Assets, Lease Liabilities, and various borrowings, across fiscal years ending March 31st for 2024, 2025, and 2026. The data shows fluctuations in these assets and liabilities over the period. Furthermore, the section details the structure and movement of share capital, including the issuance of bonus and right shares, and the details of different types of borrowings, such as secured and unsecured loans.

This section details various financial and liability items for Iberia Pharmaceuticals India Limited across three fiscal years, including provisions, borrowings, trade payables, other financial liabilities, revenue, income, cost of goods sold, employee benefit expenses, finance costs, depreciation, and other expenses. The data is presented in lakhs of Rupees, with figures for 2026, 2025, and 2024, and also for the first quarter of 2022 for certain liabilities. The data covers items such as employee benefits, short-term and secured borrowings, trade payables aging, various current and other liabilities, revenue from operations, other income, cost of goods sold, and various operating and non-operating expenses.

This section details the actuarial assumptions and liability calculations for the company's defined benefit gratuity plan, including various components like present value of obligations, service costs, interest costs, and changes in benefit obligations over several years. It also covers the bifurcation of the present value of obligation into current and non-current liabilities, as well as sensitivity analyses regarding changes in discount rates and salary increases. Furthermore, the text includes information on Corporate Social Responsibility (CSR) spending requirements and movements in lease liabilities.

This section details various financial notes, including fair value information for financial instruments, segment reporting, related party transactions, and revenue from contracts with customers. It provides comparative data for trade receivables, cash balances, trade payables, and various financial liabilities across different reporting periods. Furthermore, it outlines the methodology used for valuing these instruments and discloses transactions with related parties, including salary advances, security deposits, and loan repayments.

This section details the transition from Indian GAAP to Ind AS, including the reconciliation of the Balance Sheet as of April 1st, 2023, and subsequent periods. It outlines various adjustments made during this transition, such as the recognition of lease liabilities and right-to-use assets. Furthermore, it describes the application of Ind AS 12 for deferred tax accounting, including the recognition of new temporary differences. The text also covers aspects of capital management, including gearing ratios, and the company's framework for managing various financial risks like market, credit, and currency risks.

This section details various financial and liquidity aspects of the company, including trade receivables aging, financing arrangements, and various financial liabilities. It provides comparative data for these items across different reporting periods, along with ratio calculations such as Current Ratio, Debt-Equity Ratio, Debt Service Coverage Ratio, Return on Equity Ratio, Inventory Turnover Ratio, Trade Receivable Turnover Ratio, Trade Payable Turnover Ratio, Net Capital Turnover Ratio, Net Profit Ratio, Return on Capital Employed, and various turnover ratios. The text also includes disclosures regarding liquidity risk management, the nature of financial liabilities, and compliance with certain regulatory and transaction restrictions.

This section presents key analytical ratios as per SEBI (ICDR) Regulations for Iberia Pharmaceuticals India Limited across three financial years. The data includes metrics such as Net Worth, EBITDA, profit after tax, earnings per share, and various return metrics. The document details the methodology used for calculating these ratios, including definitions for EBITDA, earnings per share, and net worth, and clarifies the basis of the financial statements.